SCHEMBL19910562

SCHEMBL19910562

CC(C)n1cnc2ccc(C(C)(C)C)cc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 1/20 0.44
HPGD P15428 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.38
RAB9A P51151 6/20 0.38
NPC1 O15118 5/20 0.38
KDM4E B2RXH2 4/20 0.38
SMN1; SMN2 Q16637 4/20 0.36
ALDH1A1 P00352 3/20 0.36
GAA P10253 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
GFER P55789 1/20 0.36
MAPT P10636 2/20 0.35
SCN10A Q9Y5Y9 5/20 0.35
GLP1R P43220 1/20 0.34
LRRK2 Q5S007 1/20 0.34
TP53 P04637 1/20 0.34
SYK P43405 1/20 0.33
PRMT5 O14744 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13920390 0.87 HCAR3 (0.55) HCAR3HPGDMEN1KMT2AHSD17B10
SCHEMBL19848505 0.85 HCAR3 (0.43) HCAR3HPGDMEN1KMT2AHSD17B10
SCHEMBL28318793 0.83 SCN10A (0.36) HCAR3HPGDMEN1KMT2AHSD17B10
SCHEMBL14072358 0.78 USP5 (0.43) HCAR3MEN1KMT2AKDM4ELRRK2
SCHEMBL22272322 0.77 HCAR3 (0.47) HCAR3HPGDMEN1KMT2AHSD17B10
SCHEMBL7732282 0.77 RAB9A (0.50) HCAR3HPGDMEN1KMT2AHSD17B10
SCHEMBL762017 0.77 DYRK1A (0.49) HPGDHSD17B10RAB9ANPC1SMN1; SMN2
SCHEMBL12123558 0.76 NR1I2 (0.35) HCAR3SCN10ASYKKCNH2
SCHEMBL23063551 0.76 HCAR3 (0.50) HCAR3HPGDMEN1KMT2AHSD17B10
SCHEMBL7726920 0.76 HCAR3 (0.46) HCAR3HPGDMEN1KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180057458-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. 2018-03-01 US disclosed
US-20180057458-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. 2018-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180057458-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF LOXL2, LOXL1, LOX HCAR3 1830/4885HPGD 402/4885MEN1 4208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.